The elmiric acids: Biologically active anandamide analogs

被引:27
作者
Burstein, Sumner [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
Endocannabinoid; Lipoamino acid; Eicosanoid; Elmiric acid; Inflammation; Anandamide;
D O I
10.1016/j.neuropharm.2007.11.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
As chemical entities, lipoamino acids have been known for some time. However, more recently their occurrence and importance in mammalian species has been discovered. They appear to have close relationships with the endocannabinoids not only structurally but also in terms of biological actions. The latter include analgesia, anti-inflammatory effects, inhibition of cell proliferation and calcium ion mobilization. To date about 40 naturally Occurring members of this family have been identified and, additionally, several synthetic analogs have been prepared and studied. To facilitate their identity, a nomenclature system has been suggested based on the name elmiric acid (EMA). The prototypic example, N-arachidonoyl glycine, does not bind to CBI, however it does inhibit the glycine transporter GLYT2a and also appears to be a ligand for the orphan G-protein-coupled receptor GPR18. It may also have a role in regulating tissue levels of anandamide by Virtue of its inhibitory effect on FAAH the enzyme that mediates inactivation of anandamide. Its concentration in rat brain is several-fold higher than anandamide supporting its possible role as a physiological mediator. Future studies Should be aimed at elucidating the actions of all of the members of this interesting family of molecules. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1259 / 1264
页数:6
相关论文
共 47 条
  • [1] The polar-lipid composition of the sphingolipid-producing bacterium Flectobacillus major
    Batrakov, SG
    Mosezhnyi, AE
    Ruzhitsky, AO
    Sheichenko, VI
    Nikitin, DI
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1484 (2-3): : 225 - 240
  • [2] Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the litigation of PPARγ
    Bell-Parikh, LC
    Ide, T
    Lawson, JA
    McNamara, P
    Reilly, M
    FitzGerald, GA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) : 945 - 955
  • [3] The expanding field of cannabimimetic and related lipid mediators
    Bradshaw, HB
    Walker, JM
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (04) : 459 - 465
  • [4] BRADSHAW HB, 2005, ICRS S CANN CLEARW F
  • [5] BRADSHAW HB, 2006, SOC NEUR ABSTR
  • [6] Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators
    Bradshaw, Heather B.
    Rimmerman, Neta
    Krey, Jocelyn F.
    Walker, J. Michael
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2006, 291 (02) : R349 - R358
  • [7] PROSTAGLANDINS AND CANNABIS .6. RELEASE OF ARACHIDONIC-ACID FROM HELA-CELLS BY DELTA-1-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS
    BURSTEIN, S
    HUNTER, SA
    [J]. BIOCHEMICAL PHARMACOLOGY, 1978, 27 (08) : 1275 - 1280
  • [8] PHOSPHOLIPASE PARTICIPATION IN CANNABINOID-INDUCED RELEASE OF FREE ARACHIDONIC-ACID
    BURSTEIN, S
    BUDROW, J
    DEBATIS, M
    HUNTER, SA
    SUBRAMANIAN, A
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 48 (06) : 1253 - 1264
  • [9] PROSTAGLANDINS AND CANNABIS .8. ELEVATION OF PHOSPHOLIPASE-A2 ACTIVITY BY CANNABINOIDS IN WHOLE CELLS AND SUB-CELLULAR PREPARATIONS
    BURSTEIN, S
    HUNTER, SA
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (8-9) : S240 - S248
  • [10] BURSTEIN S, 1983, MOL PHARMACOL, V23, P121